# Gossamer Bio

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/gossamer-bio

- Industry: Pharmaceuticals
- Headquarters: San Diego, US
- Website: www.gossamerbio.com
- Total disclosed funding: $330M
- Latest round: Series B (Jul 23, 2018)
- Investors on record: 7

## About

Gossamer Bio, Inc. is a biopharmaceutical company dedicated to the development of innovative therapies targeting rare diseases, particularly pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).Gossamer Bio, Inc. was founded in 2017 and is headquartered in San Diego, US. The company focuses on developing treatments for pulmonary diseases and has engaged in four significant deals as part of its operational strategy. The founder and CEO, Faheem Hasnain, has a history of leading biopharmaceutical companies. The latest funding round was an IPO completed on February 7, 2019, raising USD 276 mn, which represents the total amount raised to date.Gossamer Bio primarily focuses on the development of seralutinib, an investigational inhaled drug designed to treat pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). This inhaled product operates as a PDGFRa/ß, CSF1R, and c-KIT inhibitor and is administered via a dry powder inhaler. The PROSERA Study, currently in phase 3 clinical trials, evaluates the efficacy and safety of seralutinib in adults with PAH, emphasizing the unmet medical needs in this patient population. Gossamer Bio serves patients primarily in the United States and Europe, aiming to enhance their quality of life through innovative therapeutic options.Gossamer Bio generated revenue of USD 114.70 mn in the most recent year, 2024. The company reported an EBITDA of -USD 59.92 mn for the same period. Revenue is primarily derived from partnerships and clinical trial funding related to seralutinib, where collaborations with healthcare providers and research institutions facilitate financial transactions aimed at advancing drug development.Gossamer Bio plans to advance the development of seralutinib and leverage its recent IPO funding of USD 276 mn to support further clinical trials and potential market entry. The company targets expansion into new healthcare markets in Europe and the US by the end of 2024, with a focus on enhancing access to its therapies. The funds raised from the IPO will be utilized to support ongoing clinical trials and the development pipeline, aiming to bring innovative treatments to patients with rare diseases.

## Funding rounds

- Series B, Jul 23, 2018, $230M — ARCH Venture Partners, Polaris Partners, Baupost Group, Abu Dhabi Investment Authority, Invus [DUP], Omega Funds, Hillhouse Investment
- Series A, Jan 4, 2018, $100M — ARCH Venture Partners, Omega Funds
- Seed, Jan 1, 2018 — Omega Funds

## Investors

- Omega Funds (https://capitalatlas.ai/funds/omega-funds) — Seed, Series A, Series B
- ARCH Venture Partners (https://capitalatlas.ai/funds/arch-venture-partners) — Series A, Series B
- Polaris Partners (https://capitalatlas.ai/funds/polaris-partners) — Series B
- Baupost Group — Series B
- Abu Dhabi Investment Authority — Series B
- Invus [DUP] — Series B
- Hillhouse Investment (https://capitalatlas.ai/funds/hillhouse-investment) — Series B